Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Immunome (IMNM)/b) will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.A live audio webcast will be available through the Investor Relations section of Immunome’s website. A replay of the webcast will be accessible for approximately 30 days after the live presentation.
Immunome (Nasdaq: IMNM) reported second quarter 2026 results and a broad oncology pipeline update. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $520.0 million, which Immunome expects will fund operations into 2028. Q2 2026 collaboration revenue was zero versus $4.0 million a year earlier; research and development expenses were $59.9 million and general and administrative expenses were $18.3 million, resulting in a net loss of $73.1 million (−$0.65 per share).
The U.S. FDA accepted the NDA for varegacestat in desmoid tumors, assigning an April 28, 2027 PDUFA date, following Phase 3 RINGSIDE data showing an 84% reduction in risk of progression or death and a 56% objective response rate. Phase 1 studies of IM-1617 and IM-3050 began dosing in mid‑2026, and IM-1021 continues with objective responses observed in B‑cell lymphoma.
Immunome (Nasdaq: IMNM) reported that its Board’s Compensation Committee granted inducement stock option awards on August 3, 2026 to nine new employees under the 2024 Inducement Plan. The options cover an aggregate 176,500 shares at an exercise price of $23.01 per share, equal to that day’s closing price.
The options vest over four years, with 25% vesting after one year and the remaining shares vesting monthly over the following 36 months, subject to continued service. The awards were approved as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and are governed by the plan and related option agreements.
Immunome (Nasdaq: IMNM) reported dosing the first patient in its Phase 1, first-in-human trial of IM-3050, a fibroblast activation protein (FAP)-targeted radioligand therapy using radioactive lutetium-177 in patients with FAP-expressing advanced solid tumors.
The open-label, multicenter study includes dose escalation and expansion phases to assess safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity. Dose escalation will evaluate repeated escalating doses to establish the maximum tolerated or recommended expansion dose, which will then be further assessed for safety and tolerability in the expansion phase.
Immunome (Nasdaq: IMNM) announced FDA acceptance of its New Drug Application for varegacestat, an oral, once-daily gamma secretase inhibitor for adults with desmoid tumors. The FDA set a PDUFA target action date of April 28, 2027.
The NDA is supported by the Phase 3 RINGSIDE trial, which met its primary endpoint with an 84% reduction in risk of disease progression or death vs. placebo (hazard ratio 0.16, p<0.0001). Key secondary endpoints were also met, including an objective response rate of 56% vs. 9% and significant pain reduction. Varegacestat showed a median best tumor volume change of -83% vs. +11% with placebo and was generally well tolerated; 95% of adverse events were grade 1 or 2.
Immunome (Nasdaq: IMNM) granted inducement stock options to seventeen new employees under its 2024 Inducement Plan on July 1, 2026. Awards cover an aggregate 344,000 shares at a per-share exercise price of $21.49, vesting over four years, consistent with Nasdaq Listing Rule 5635(c)(4).
Immunome (Nasdaq: IMNM) dosed the first patient in a Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC for advanced solid tumors. IM-1617 uses Immunome’s proprietary HC74 TOP1 inhibitor payload. The open-label, multicenter study will assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity in colorectal, non-small cell lung, breast and other solid tumors. Immunome also plans IND submissions for ADC candidates IM-1340 and IM-1335 in mid- and late 2026, respectively.
Immunome (Nasdaq: IMNM) announced that its Board Compensation Committee granted inducement stock option awards on June 1, 2026, under the 2024 Inducement Plan.
The awards cover 353,000 shares for twenty new employees at an exercise price of $20.78 per share, vesting over four years per Nasdaq Rule 5635(c)(4).
Immunome (Nasdaq: IMNM) reported detailed Phase 3 RINGSIDE results for varegacestat in adults with progressing desmoid tumors at the 2026 ASCO Meeting.
Varegacestat met the primary and all key secondary endpoints, showing significant benefits in progression-free survival, response rate, pain reduction, tumor volume and supporting an NDA filed with the FDA in April 2026, with an EMA MAA planned by end of 2026.
Immunome (Nasdaq: IMNM) announced that its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:40 a.m. EDT.
A live audio webcast and 30-day replay will be available via the company’s investor relations website.